CIK 0000875045
- Large accelerated filer
BIOGEN INC.
Sign in to watch- Ticker
- BIIB
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 330112644
- Phone
- +1 617-679-2000
- Business address
- 225 BINNEY STREET, CAMBRIDGE, MA, 02142
- Former names
- BIOGEN IDEC INC., BIOGEN IDEC INC, IDEC PHARMACEUTICALS CORP / DE, IDEC PHARMACEUTICALS CORP / CA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-02-28 | Sandrock Alfred EVP CMO Neuro & Neurodegenerat | Shares withheld for taxes | −188 | $284.75 | $54K | 9,147.86 |
| 2017-02-28 | Sandrock Alfred EVP CMO Neuro & Neurodegenerat | Shares withheld for taxes | −727 | $274.76 | $200K | 8,420.86 |
| 2017-02-28 | Sandrock Alfred EVP CMO Neuro & Neurodegenerat | Exercise or conversion | +1,569 | 9,989.86 | ||
| 2017-02-28 | Sandrock Alfred EVP CMO Neuro & Neurodegenerat | Shares withheld for taxes | −739 | $274.76 | $203K | 9,250.86 |
| 2017-02-28 | Sandrock Alfred EVP CMO Neuro & Neurodegenerat | Exercise or conversion | +628 | 9,878.86 | ||
| 2017-02-28 | Sandrock Alfred EVP CMO Neuro & Neurodegenerat | Shares withheld for taxes | −296 | $274.60 | $81K | 9,582.86 |
| 2017-02-28 | Sandrock Alfred EVP CMO Neuro & Neurodegenerat | Exercise or conversion | +815 | 10,397.86 | ||
| 2017-02-28 | Sandrock Alfred EVP CMO Neuro & Neurodegenerat | Shares withheld for taxes | −384 | $274.76 | $106K | 10,013.86 |
| 2017-02-28 | Sandrock Alfred EVP CMO Neuro & Neurodegenerat | Other disposition · Restricted Stock Unit | −1,841 | 8,397 | ||
| 2017-02-28 | Sandrock Alfred EVP CMO Neuro & Neurodegenerat | Other disposition · Restricted Stock Unit | −738 | 628 | ||
| 2017-02-28 | Sandrock Alfred EVP CMO Neuro & Neurodegenerat | Other disposition · Restricted Stock Unit | −1,103 | 6,335 | ||
| 2017-02-28 | Sandrock Alfred EVP CMO Neuro & Neurodegenerat | Other disposition · Restricted Stock Unit | −662 | 1,460 | ||
| 2017-02-28 | Sandrock Alfred EVP CMO Neuro & Neurodegenerat | Exercise or conversion · Restricted Stock Unit | −1,375 | 4,960 | ||
| 2017-02-28 | Sandrock Alfred EVP CMO Neuro & Neurodegenerat | Exercise or conversion · Restricted Stock Unit | −398 | 1,062 | ||
| 2017-02-28 | Sandrock Alfred EVP CMO Neuro & Neurodegenerat | Exercise or conversion · Restricted Stock Unit | −1,569 | 6,828 | ||
| 2017-02-28 | Sandrock Alfred EVP CMO Neuro & Neurodegenerat | Exercise or conversion · Restricted Stock Unit | −628 | 0 | ||
| 2017-02-28 | Sandrock Alfred EVP CMO Neuro & Neurodegenerat | Exercise or conversion · Restricted Stock Unit | −815 | 0 | ||
| 2017-02-28 | ALEXANDER SUSAN H EVP, Chief Legal Officer | Exercise or conversion | +728 | 32,568 | ||
| 2017-02-28 | ALEXANDER SUSAN H EVP, Chief Legal Officer | Shares withheld for taxes | −335 | $284.75 | $95K | 32,233 |
| 2017-02-28 | ALEXANDER SUSAN H EVP, Chief Legal Officer | Exercise or conversion | +1,375 | 33,608 |
Page 64 of 73 · 1,456 trades